Table 2. LOH status, mutation results and clinicopathological features of primary ovarian tumours.

	Clinicopathology						LOH			Mutations or SNPs
Case	Histo	Stage	Grade	D8S137	D8S1048	Spanning exon	nta	Codon	Base change	a.a change
35/87	SER	3C	3	LOH	LOH	5	25044	137	CTT→TTTb	Leu→Phe
69/89	SER	3	2	NI	LOH
35/90	SER	3B	2/3	NL	NL	4	24147	IVS3-56	Del Gb and T→Ca	Intronic
5/91	SER	2A	2/3	NI	NL		24752	IVS3-61		Intronic
23/91	ENDO	3	2	LOH	LOH	5	25199	IVS5+15	A→G	Intronic
33/91	ENDO	4	3	LOH	LOH
44/91	SER	3C	3	NI	LOH	5	25199	IVS5+15	A→G	Intronic
45/91	SER	3C	NS	LOH	LOH
52/91	SER	2B	2	NI	NL	5	25199	IVS5+15	A→G	Intronic
59/91	SER	3	3	NL	NI	5	25199	IVS5+15	A→G	Intronic
68/91	SER	3	3	NL	NL
2/92	SER	3	2	NL	NI	5	25199	IVS5+15	A→G	Intronic
3/92	SER	3	3	LOH	LOH	5	25199	IVS5+15	A→G	Intronic
4/92	SER	3B	3	NI	NL
23/92	SER	3	3	CR	CR
26/92	CCC	4	2	LOH	LOH	2	8194	61	TCA→TCTb	Ser→Ser
						5	25199	IVS5+15	A→G	Intronic
39/92	SER	3	2	NI	NI
52/92	SER	3	2	NI	NL	5	25199	IVS5+15	A→G	Intronic
62/92	SER	3C	2/3	LOH	LOH
66/92	ENDO	3C	3	NI	NL
67/92	ENDO	1C	2/3	NL	NL
76/92	SER	3	2/3	LOH	NI	5	25199	IVS5+15	A→G	Intronic
3/93	SER	3C	3	NL	CR	2	8243	IVS2+11	C→T	Intronic
4/93	SER	3	1/2	NL	CR	5	25199	IVS5+15	A→G	Intronic
5/93	SER	3C	2/3	NI	NI
6/93	SER	3C	2/3	LOH	NI
8/93	SER	3C	2/3	LOH	LOH
10/93	SER	3C	2/3	NL	NL	5	25199	IVS5+15	A→G	Intronic
12/93	CCC	3	2/3	NI	NL	2	8209	66	TCC→TCAb	Ser→Ser
13/93	SER	3C	NS	NI	NI
35/93	SER	3C	3	NI	LOH
61/93	ENDO	4	2	NI	LOH	2	8209	66	TCC→TCGb	Ser→Ser
						5	25199	IVS5+15	A→G	Intronic
65/93	ENDO	3	2/3	NI	NI	5	25199	IVS5+15	A→G	Intronic
99/93	ENDO	4	3	NL	NL	5	25199	IVS5+15	A→G	Intronic
108/93	SER	3C	2	NL	NI	5	25199	IVS5+15	A→G	Intronic
14/94	SER	1A	NS	NL	NL
23/94	SER	3	3	NI	NL	5	25199	IVS5+15	A→G	Intronic
25/94	SER	3C	2	NL	NL
34/94	SER	3C	3	NI	ND	5	25199	IVS5+15	A→G	Intronic
70/94	SER	3C	2	NL	ND

^aBases counted from ATG start codon; NS=not specified; NL=no loss; LOH=loss of heterozygosity; NI=not informative; CR=can't read; ND=not done.